Broseta J, García-March G, Sánchez-Ledesma M J, Anaya J, Silva I
Department of Neurosurgery, University of Salamanca, Spain.
Stereotact Funct Neurosurg. 1990;54-55:147-53. doi: 10.1159/000100205.
On the basis of previous experimental and clinical studies, 14 patients with severe spasticity due to central or spinal cord damage, resistant to all conservative treatments, were selected after a percutaneous trial period for chronic intrathecal baclofen infusion by programmable pumps. The agent was delivered at C4 in quadriplegic patients or in cases with central spasticity and in the neighbouring areas on the affected segments in paraplegic patients. The daily baclofen dose varied from 25 to 260 micrograms and was infused in a bolus, continuously infused or both combined according to the results during the trial period. After a mean follow-up period of 11 months, constant decrease of rigidity, absence of spasms, improvement of bladder function, cramping pain remission, and moderate improvement in walking capacity and transfer activities were usually observed. Neither complications nor side effects were noted.
基于先前的实验和临床研究，在经过经皮试用可编程泵进行慢性鞘内注射巴氯芬的试验期后，选择了14例因中枢或脊髓损伤导致严重痉挛且对所有保守治疗均无效的患者。对于四肢瘫痪患者或中枢性痉挛患者，药物在C4水平给药；对于截瘫患者，药物在受影响节段的相邻区域给药。巴氯芬的每日剂量从25微克到260微克不等，根据试验期的结果，以推注、持续输注或两者结合的方式给药。平均随访11个月后，通常观察到肌张力持续降低、痉挛消失、膀胱功能改善、绞痛缓解，步行能力和转移活动有中度改善。未发现并发症和副作用。
